Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Adhera Therapeutics
Adhera Therapeutics to Collaborate with Alberta Diabetes Institute, University of Alberta to Initiate Clinical Trial of MLR-1023 in Type 1 Diabetes
Read full article Adhera Therapeutics, Inc. Data will be instrumental in upcoming Phase 2 clinical trial of MLR-1023, Adhera’s novel Type 1 Diabetes drug candidate Company moving forward with application to transition from OTC to NASDAQ Baton Rouge, LA, Jan. 25, 2023 (GLOBE NEWSWIRE) -- Adhera Therapeutics, Inc.
Adhera Therapeutics to Collaborate with Alberta Diabetes Original
Data will be instrumental in upcoming Phase 2 clinical trial of MLR-1023, Adhera’s novel Type 1 Diabetes drug candidate Company moving forward with application to transition from OTC to NASDAQ Baton Rouge, LA, Jan. 25, 2023 (GLOBE NEWSWIRE) -- Adhera Therapeutics, Inc.
Side Effects, Uses, Dosage, Interactions, Warnings
WARNING FETAL TOXICITY When pregnancy is detected, discontinue PRESTALIA as soon as possible[see WARNINGS AND PRECAUTIONS]. Drugs that act directly on the renin-angiotens in system can cause injury and death to the developing fetus [see WARNINGS AND PRECAUTIONS]. Description for Prestalia PRESTALIA is a combination of perindopril arginine and amlodipine besylate. Perindopril arginine is the L-arginine salt of perindopril, the ethyl ester of a non-sulfhydryl angiotensin converting enzyme inhibitor.
Adhera Therapeutics Announces CEO, Senior Management Original
Baton Rouge, LA, Sept. 19, 2022 (GLOBE NEWSWIRE) -- Adhera Therapeutics, Inc. (OTCQB: ATRX) ("Adhera" or the "Company"), a clinical stage biopharmaceutical company, today announces that on September 8, 2022, the Company’s Board of Directors (the “Board”) appointed Zahed Subhan PhD MBA JD as Chief Executive Officer of Adhera Therapeutics, effective September 30, 2022. The same day, Dr. Subhan was elected to serve as Chairman of the Board.
Adhera Therapeutics Signs Letter of Intent to Acquire Original
Baton Rouge, LA, July 19, 2022 (GLOBE NEWSWIRE) -- Adhera Therapeutics, Inc. (OTCQB: ATRX) ("Adhera" or the "Company"), a clinical stage biopharmaceutical company, today announces that the Company has entered a Heads of Terms (also known as a Letter of Intent (“LOI”)) agreement with Bio Innovation Group to acquire Paclitaxel Gallium Transferrin (“PGT”), a novel protein complex for targeted treatment of advanced cancers.
Adhera Therapeutics Appoints Trond K. Waerness as Chairman
Baton Rouge, LA, May 19, 2022 (GLOBE NEWSWIRE) -- Adhera Therapeutics, Inc. (OTCQB: ATRX) ("Adhera" or the "Company"), a clinical stage biopharmaceutical company, is pleased to announce the appointment of Trond K. Waerness as Chairman of the Company’s Board of Directors. Mr. Waerness has been serving as a Director at Adhera since April 2021. Mr. Waerness is a pharmaceutical executive with approximately 25 years of experience in all areas of pharmaceutical commercialization.
Adhera Therapeutics Names Preeminent Diabetes Pioneer Dr. Original
Baton Rouge, LA, March 21, 2022 (GLOBE NEWSWIRE) -- Adhera Therapeutics, Inc. (OTCPK: ATRX) ("Adhera" or the "Company"), a clinical stage biopharmaceutical company, is pleased to announce the appointment of Jean Buteau, PhD., to the Company’s Scientific Advisory Board.
Adhera Therapeutics Announces Uplisting to OTCQB Venture
Baton Rouge, LA, Jan. 20, 2022 (GLOBE NEWSWIRE) -- Adhera Therapeutics, Inc. (OTCPK: ATRX) ("Adhera" or the "Company"), a clinical stage biopharmaceutical company, is pleased to announce its successful uplisting from the OTC Pink Sheets to the OTCQB® Venture Marketplace (the “OTCQB”).
Adhera Therapeutics Announces Uplisting to OTCQB Venture Marketplace
Baton Rouge, LA, Jan. 20, 2022 (GLOBE NEWSWIRE) -- Adhera Therapeutics, Inc. (OTCPK: ATRX) ("Adhera" or the "Company"), a clinical stage biopharmaceutical company, is pleased to announce its successful uplisting from the OTC Pink Sheets to the OTCQB® Venture Marketplace (the “OTCQB”).
Adhera Therapeutics Receives Notice of Allowance for New Canadian Patent Covering MLR-1019 for Dyskinesia and Related Disorders
Baton Rouge, LA, Nov. 22, 2021 (GLOBE NEWSWIRE) -- Adhera Therapeutics, Inc. (OTCPK: ATRX) ("Adhera" or the "Company"), a clinical stage biopharmaceutical company, is pleased to announce that a new Canadian patent has been issued for MLR-1019 (armesocarb), a drug licensed by the Company from Melior Discovery (“Melior”) company Melior Pharmaceuticals II, LLC (“Melior 2”).
Adhera Therapeutics Announces Appointment of Dr. Zahed Original
Baton Rouge, LA, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Adhera Therapeutics, Inc. (OTCPK: ATRX) ("Adhera" or the "Company"), a clinical stage biopharmaceutical company, is pleased to announce the appointment of Zahed Subhan, BS MS PhD MBA LLB, to the Company’s Board of Directors. Dr. Subhan is an international pharmaceutical and biotechnology executive with more than 30 years’ experience in the United States, United Kingdom, European Union, and Asia.
Adhera Receives European Patent Covering MLR-1019 and Derivatives for Treating Dyskinesias
Baton Rouge, LA, Oct. 04, 2021 (GLOBE NEWSWIRE) -- Adhera Therapeutics, Inc. (OTCPK: ATRX) ("Adhera" or the "Company"), a clinical stage biopharmaceutical company, is pleased to announce that a new European patent has been issued for MLR-1019 (armesocarb), a drug licensed by the Company from Melior Discovery (“Melior”) company Melior Pharmaceuticals II, LLC (“Melior 2”).
Adhera Therapeutics Provides Insight on Corporate Strategy, Original
September 13, 2021 10:28 ET | Source: Adhera Therapeutics, Inc. Adhera Therapeutics, Inc. City of Industry, UNITED STATES Baton Rouge, LA, Sept. 13, 2021 (GLOBE NEWSWIRE) -- Adhera Therapeutics, Inc. (OTCPK: ATRX) ("Adhera" or the "Company"), a clinical stage biopharmaceutical company, today provides shareholders an update on corporate strategy and planned clinical development of MLR-1019 (armesocarb) and MLR-1023 (tolimidone).
Adhera Signs Definitive License Agreement with Melior Pharmaceuticals II for New Parkinson’s Disease Drug Candidate
Adhera to develop MLR-1019 (armesocarb) as a new class of drug for Parkinson’s Disease (PD), representing the only drug to address both movement and non-movement symptoms of PD Armesocarb is the active enantiomer in mesocarb, a drug marketed in Europe for 37 years for various psychiatric and central nervous system indications Companies expect to leverage existing safety and related data to move MLR-1019 directly into a Phase 2a clinical trial Baton Rouge, LA, July 29, 2021 (GLOBE NEWSWIRE) --...
Adhera Therapeutics Signs Letter of Intent with Melior Pharmaceuticals II to Acquire a New Class of Drug for Parkinson’s Disease
Adhera to acquire and develop MLR-1019 (armesocarb), the API in mesocarb – a drug previously sold in Europe for 37 years – for Parkinson’s Disease MLR-1019, a Phase 2-ready product, could have substantial benefits over today’s Parkinson’s drugs, including being the first to address both movement and non-movement symptoms Baton Rouge, LA, June 07, 2021 (GLOBE NEWSWIRE) -- Adhera Therapeutics, Inc.
Adhera Therapeutics (ATRX) - Strategic SWOT Analysis Review [Published by Global Data]
Introduction Adhera Therapeutics (ATRX) - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services.
Adhera Therapeutics Provides Third Quarter 2018 Financial Results and Business Update
Adhera Therapeutics Provides Third Quarter 2018 Financial Results and Business Update World News: 00:08 GMT Wednesday 21st November 2018. [Adhera Therapeutics, Inc. via Globe Newswire via SPi World News] Research Triangle Park, NC, Nov. 20, 2018 (GLOBE NEWSWIRE) -- Adhera Therapeutics, Inc.
Adhera Therapeutics (MRNA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile [Report Updated: 09-11-2018]
Introduction Summary Adhera Therapeutics (Adhera) is a nucleic acid-based drug discovery and development company that focuses on rare diseases. It focuses on treating the intersection of arthritis, hypertension, pain, and cancer using combination therapies of already approved drugs. The company is developing and commercializing late stage, non-addictive pain therapeutics.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Adhera
Contact Adhera, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack